Spark Therapeutics Announces Pricing and First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment

January 3, 2018



Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced three new payer programs: an outcomes-based rebate arrangement with a long-term durability measure, an innovative contracting model and a proposal to CMS under which payments for LUXTURNA™ (voretigene neparvovec-rzyl) would be made over time. The price of the therapy is to be set at $ 850 000 per patient.


Read more at Spark Therapeutics website.



Please reload

Please reload

Please reload

4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2020 by 4BIO Ventures Management Ltd